Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NVG 291 (Primary)
  • Indications Spinal cord injuries
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CONNECT
  • Sponsors NervGen Pharma

Most Recent Events

  • 02 Jun 2025 According to a NervGen Pharma media release, the company plans to meet with the FDA in the coming months to discuss these results and the path forward for NVG-291. In addition, we continue to enroll participants in the subacute cohort (20-90 days post injury) of the trial.
  • 02 Jun 2025 Primary(Connectivity in a leg muscle (tibialis anterior) end point was not met, according to a NervGen Pharma media release.
  • 02 Jun 2025 Primary (MEP amplitudes (corticospinal contribution) in two specific target muscle groups) endpoint has been met, According to a NervGen Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top